ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx']
$bntx interim data of bnt316/onc-392 from the ongoing phase 1/2 trial to be presented at this year s asco annual meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, pd-(l)1-resistant nsclc. 
notrel⟳ad is an Ai-based web service that helps users automating public web content monitoring for investing and trading purposes. Not advice. Twitter delayed.